Dyax Corp. (NASDAQ: DYAX) announced today that executive management will participate in the Leerink Partners Rare Disease Roundtable being held October 1, 2014 at the Le Parker Meridien Hotel in New York City and is scheduled to present at 11:30am (ET) that day. The Company will provide a corporate update on the Company’s key value drivers – the KALBITOR® (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
Help employers find you! Check out all the jobs and post your resume.
